SCHEMBL3747597

SCHEMBL3747597

[c]1nnoc1-c1conn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1169059 0.68 KDM4E (0.34)
SCHEMBL1032107 0.67 KMT2A (0.37)
SCHEMBL4843148 0.65
SCHEMBL28271180 0.64 ENPP3 (0.31)
SCHEMBL17185665 0.64
SCHEMBL4506799 0.63
SCHEMBL4728163 0.61
SCHEMBL69570 0.61
SCHEMBL2340955 0.60
SCHEMBL5218684 0.60

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2781512-B1 OXADIAZOLE COMPOUND AND PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF UNIV SHANGHAI JIAOTONG (CN) 2017-06-28 EP claimed
EP-2167487-A1 PYRROLE DERIVATIVES AS P2Y12 ANTAGONISTS Sanofi-Aventis (FR) 2010-03-31 EP claimed
WO-2008155022-A1 PYRROLE DERIVATIVES AS P2Y12 ANTAGONISTS SANOFI-AVENTIS (FR) 2008-12-24 WO claimed
CN-117120090-A HPK1 antagonists and uses thereof 林伯士萨顿公司 2023-11-24 CN disclosed
EP-3043774-A2 LIQUID PROTEIN FORMULATIONS CONTAINING IONIC LIQUIDS Arsia Therapeutics, Inc. (US) 2016-07-20 EP disclosed
WO-2015038811-A2 LIQUID PROTEIN FORMULATIONS CONTAINING IONIC LIQUIDS Arsia Therapeutics, Inc. (US) 2015-03-19 WO disclosed
EP-1888567-B1 HETEROARYL-CARBOXYLIC ACID (SULFAMOYL ALKYL) AMIDE - DERIVATIVES AS FACTOR XA INHIBITORS SANOFI AVENTIS (FR) 2009-12-16 EP disclosed
EP-1633746-A1 NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS Sanofi-Aventis Deutschland GmbH (DE) 2006-03-15 EP disclosed
WO-2004101554-A1 NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2004-11-25 WO disclosed